Bristol Myers Squibb's First-Quarter 2024 Financial statements

Bristol Myers Squibb's first-quarter performance demonstrates its commitment to long-term growth, with revenues reaching $11.9 billion, a 5% increase (6% adjusting for foreign exchange). Notable transactions, including acquisitions and collaborations, have bolstered the company's portfolio.

Key Highlights

• Q1 revenues: $11.9 billion, up 5% (6% adjusted for foreign exchange).
• Growth portfolio revenues: $4.8 billion, up 8% (11% adjusted for foreign exchange).
• Strategic acquisitions: Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune.
• GAAP loss per share: $(5.89); Non-GAAP loss per share: $(4.40).
• U.S. approval of Abecma and Breyanzi for various cancers.
• Strategic productivity initiative aims to deliver $1.5 billion in cost savings.

First Quarter Results

Revenues rose to $11.9 billion, driven by strong performance of key products like Eliquis, Reblozyl, and Opdualag. U.S. revenues surged by 7% to $8.5 billion, while international revenues remained flat at $3.4 billion. However, gross margin decreased due to product mix.

Business Development

Bristol Myers Squibb expanded its portfolio through strategic acquisitions, including Karuna Therapeutics, RayzeBio, and Mirati Therapeutics. These transactions strengthen the company's pipeline and long-term growth prospects. Additionally, collaborations such as the agreement with SystImmune and Cellares further enhance its position in oncology and cell therapies.

Data Source: https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2024/default.aspx